On August 14, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2025 and provided a business update. The company recently presented positive results from the Phase 1 clinical trial of CDI-988 at the 2025 Military Health System Research Symposium. The data showed that all doses of CDI-988, from 100 mg to 1200 mg, were well tolerated. In addition, there were no severe treatment-emergent adverse events, no clinically relevant ECG changes, and no clinically significant pathology results. The company will now turn its attention to conducting a Phase 1b norovirus challenge study, which we estimate will commence in the fourth quarter of 2025 following the clearance of the IND by the FDA.
